GAMB - GMB

El interés en corto de Gambling.com Gr da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Gambling.com Gr. Los datos de interés en corto se actualizan cada dos semanas.

Gambling.com Gr (NASDAQ:GAMB) Bolsa, Informe de interés en corto

Gambling.com Gr

Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casinos online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.

Gambling.com Group Limited - Ordinary Shares

Gambling.com Group Ltd

GAMB

Gambit Energy Inc

News

White House Adviser Hassett On CNBC, Said U.S. Seeking Rare Earths Agreement With China in London; Expects Export Controls To Be Eased

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/09073304/QuantaSing-0609-900x600-1.png" alt="" class="wp-image-14089" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/09073304/QuantaSing-0609-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/09073304/QuantaSing-0609-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/09073304/QuantaSing-0609-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The adult education company's shares have tripled since it disclosed a plan to enter the collectible toy business through a major acquisition that closed on March 31
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>QuantaSing closed its purchase of collectible toy developer Letsvan at the end of March, and expects the purchase to make a "significant" revenue contribution in its June quarter</li>
<li>Revenue from the company's core adult education services plunged by 40% in its latest quarter, as it focused on customer quality over quantity</li>
</ul>
QuantaSing Group Ltd.&nbsp;(QSG.US) is learning there are many ways to get cautious consumers to part with their hard-earned money in a sluggish economy.
First, it did that by selling education products to adults, playing on the deeply engrained value Chinese place on self-improvement for themselves and their children. Now it's discovered something people like even more in such economically uncertain times. That something is toys for adults, part of what's locally called the "good economy" that refers to products that help people play in the present to avoid thinking too much about the future.
Discussion of QuantaSing's recent movement into collectible toys was the highlight of its&nbsp;<a href="https://www.globenewswire.com/news-release/2025/06/06/3094949/0/en/QuantaSing-Announces-Unaudited-Financial-Results-for-the-Third-Quarter-of-Fiscal-Year-2025.html">latest quarterly results</a>&nbsp;announced last Friday. The company's announced that it completed its purchase of 61% of&nbsp;Shenzhen Yiqi Culture Co. Ltd.&nbsp;on March 31 for 235 mln yuan ($33 million) in cash. Yiqi's main asset is&nbsp;Letsvan, which makes collectible toys for adults that have become all the rage in China lately.
QuantaSing's legacy adult education business was less impressive in the quarter through March, the company's third fiscal quarter. Revenue for its core businesses of providing financial literacy and skills upgrading courses tumbled by nearly half, as it focused on the most profitable customers over simply chasing big numbers.
Even in its core education business, the company is finding some early success by developing more leisure-oriented products like combining education with hobbies like calligraphy and travel. The popularity of such products seems to reflect a growing desire by Chinese to enjoy the present through hobbies like calligraphy, buying collectible toys and dressing up as their favorite anime characters. A more traditional preference for self-improvement education seems to be taking a back seat in the current economic slowdown, probably the result of a weak job market.
"Pop toys have become powerful vehicles for self-expression, particularly among millennials and Gen Z. The sector has proven resilient with key players sustaining strong growth even in economic downturns," said Chairman Li Peng on the company's earnings call. "Today's consumer is (increasingly interested in) emotional value over pure functionality. They are seeking comfort, identity affirmation and connection through their purchases. And the pop toys deliver exactly that."
Investors have gobbled up QuantaSing's transformation story. The company's shares have tripled over the last three months, including a nearly 20% jump on Friday after the latest earnings announcement. The stock currently trades at a forward price-to-earnings (P/E) ratio of 23, which looks strong compared with the 13 for education services leader&nbsp;New Oriental&nbsp;(EDU.US; 9901.HK). But QuantaSing probably hopes to eventually achieve a multiple closer to the 47 for&nbsp;Pop Mart&nbsp;(9992.HK), whose shares have skyrocketed over the last year on the huge success for its collectible toys, including the wildly popular Labubu series.
QuantaSing spent much of its earnings release and conference call discussing the Letsvan acquisition, whose results will be included in its next financial quarter for the three months through June. Despite queries from analysts on Letsvan's future revenue contribution, CFO Xie Dong would only say that the "pop toy business will account for a very significant level of overall revenue at the consolidated level in the next quarter."
<h4 class="wp-block-heading">Aggressive expansion</h4>
QuantaSing said it has big plans for Letsvan, both domestically and internationally. Letsvan traditionally licensed its characters, with names like Wakuku, to third parties like retailer&nbsp;Miniso&nbsp;(MNSO.US; 9896.HK), which sells the toys in its separate Top Toy chain of stores that it's&nbsp;<a href="https://thebambooworks.com/brief-miniso-hires-underwriters-for-top-toy-ipo/">preparing to spin off</a>&nbsp;for a separate IPO.
QuantaSing plans to continue such third-party licensing, but also intends to develop its own chain of stores, similar to Pop Mart and Top Toy. The company revealed that it took its first step in that direction by opening a pop-up store at a popular Beijing shopping mall on May 24.
Letsvan has also taken some initial steps outside China, and will accelerate that campaign under QuantaSing's ownership. "International expansion initiatives are underway," the company said in its earnings announcement. "Letsvan has already established its footprints in certain Southeast Asian markets and has been exploring opportunities in other overseas markets, including the United States."
The company has certainly built up huge expectations for its move into collectible toys, which could make its stock vulnerable if its first results including Letsvan aren't as impressive as many investors are hoping.
One thing QuantaSing has in its favor is its ability to run an extremely profitable education business, even if that business is shrinking. Its gross margin was 83.1% in the quarter through March, which was down slightly from 84.6%, but well ahead of Pop Mart's 63.9% gross margin last year. We can probably expect QuantaSing's margin to come down after it includes the new toy business, and investors will be watching closely to see by how much.
We'll close with a quick look at the company's core education services, which are rapidly contracting but still quite profitable. QuantaSing's revenue fell 40% year-on-year to 571 million yuan in the three months to March from 946 million yuan a year earlier. It blamed the plunge on a 44% decline in revenue from its individual online learning services, which account for more than 80% of its total.
But the company also did a good job controlling costs, with the result that both its net income and adjusted net income rose year-on-year to 41.1 million yuan and 37.8 million yuan, respectively. The company had 1.13 billion yuan in cash and short-term investments at the end of March, up from 1.03 billion yuan at the end of June last year, showing it has plenty of financial resources to facilitate its integration and expansion of Letsvan's toy business.
CFO Xie hinted at some heavy spending ahead during that process, which could eat into QuantaSing's profits and profitability over the near-term.
"With our healthy cash position, we have the flexibility to support both our existing operations and our strategic initiatives in the pop toys space," Xie said on the earnings call. "Though we anticipate some near-term profitability fluctuations as we optimize our business mix, our financial foundation remains robust as we execute this strategic evolution."

Equities

Gaming

Education

Opinion

Signals

Trading Ideas

Why This Stock Tripled In The Last 3 Months

Guidance

ALAR

Alarum Technologies Now Sees Q2 Revenue Of About $8.8M, Plus Or Minus 3%, Vs Prior Estimate Of $7.9M, Plus Or Minus 3%

Plug's electrolyzer technology has been selected as the foundation of a new $5.5 billion green chemical production facility in Uzbekistan that will produce sustainable aviation fuel, green urea, and green diesel. The project is backed by the Government of Uzbekistan and further strengthens Plug's position as the preferred electrolyzer provider for global-scale decarbonization initiatives.
The Uzbekistan project builds on Allied Green's previously announced 3 GW electrolyzer commitment for its flagship green ammonia facility in Australia. The project remains on track for a final investment decision in the fourth quarter of 2025.
 &nbsp;

PLUG

Plug Power's Electrolyzer Technology Chosen As Foundation Of New $5.5B Green Chemical Production Facility In Uzbekistan To Produce Sustainable Aviation Fuel, Green Urea, And Green Diesel

Plug Power and Allied Green Leadership attending International Investment Forum to Execute the Agreement
Allied Green Continues to Make Meaningful Progress in its Green Ammonia Plant in Australia with Plug to supply 3GW of Electrolyzer Capacity Bringing the total opportunity between partners to 5GW globally
SLINGERLANDS, N.Y., June 09, 2025 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>), a global leader in comprehensive hydrogen solutions, today announced a significant expansion of its partnership with Allied Green Ammonia (AGA), with a new 2 gigawatt (GW) electrolyzer opportunity tied to a sustainable fuels project in Uzbekistan. The deal will be executed during the Tashkent International Investment Forum, where Sanjay Shrestha, President of Plug, and Alfred Benedict, Managing Director of Allied Green, will be on site for the official signing.

Plug Power Expands Partnership With Allied Green Ammonia, With New 2 GW Electrolyzer Opportunity Tied To Sustainable Fuels Project In Uzbekistan

<ul>
<li>FDA Orphan Products Grants are awarded based on rigorous scientific and technical review by rare disease and regulatory experts</li>
<li>Up to $2.6 million in non-dilutive funding anticipated over the grant period</li>
<li>Top-line data from SELVA expected in the first quarter of 2026</li>
</ul>

Biotech

Health Care

General

PVLA

Palvella Therapeutics Receives The Initial Proceeds From A Previously Announced Grant From FDA Office Of Orphan Products Development, The Grant Supports Its Ongoing Phase 3 SELVA trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) with a Buy and raises the price target from $53 to $56.

Price Target

Analyst Ratings

BBIO

HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $56

Prairie Operating Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROP#NASDAQ">PROP</a>) (the "Company" or "Prairie"), an independent energy company engaged in the development and acquisition of oil and natural gas resources in the Denver-Julesburg (DJ) Basin, today announced the reaffirmation of its multi-year Reserve-Based Lending ("RBL") credit facility with Citibank, N.A., its lead arranger.
Following its semi-annual redetermination, the Company's reserve-based credit facility was reaffirmed with a borrowing base of $475 million, a maximum facility size of $1.0 billion, and a maturity date of March 26, 2029.

PROP

Prairie Operating Reaffirms $1B, Multi-Year Reserve-Based Lending Credit Facility With Citibank, Maturity Date March 26, 2029

Medicus Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDCX#NASDAQ">MDCX</a>) ("Medicus" or the "Company") is pleased to announce submission of a comprehensive product development plan to treat external squamous cell carcinoma (SCC) under Investigational New Animal Drug (INAD File No.013880).

MDCX

Medicus Pharma Announced Submission of Product Development Plan To The FDA To Treat External Squamous Cell Carcinoma (SCC) In Horses

<a href="https://www.globenewswire.com/Tracker?data=kVc1PX3ewLfFwoYWkpegoq62-6i9h7Yk8jIa5p-aCoDgF8lczPlR80cznENh7oSlbus1bV9gxtWEilYdt6RjVcQDNvcZyXbcGBug7rriDqOJvbYN-lFLVl1YLZES4z5fcjrPNO5-NJSRtwFH1CiIrbvUs8j1fDDiNCetjeLhZGY=">PolyPid Ltd.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced positive topline results from its pivotal SHIELD II Phase 3 trial of D-PLEX100&nbsp;for the prevention of SSIs in patients undergoing abdominal colorectal surgery with large incisions, which has received Fast Track designation from the FDA.
"The positive results of our Phase 3 pivotal trial provide clear and compelling evidence of D-PLEX100's ability to significantly reduce SSIs, a major burden on patients and healthcare systems, while improving clinical outcomes for both patients and physicians," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "D-PLEX100 has the potential to meaningfully lower costs for hospitals and payers, and we believe it will be a valuable addition to the standard of care. Targeting a total addressable U.S. market of over 12 million annual surgeries and a significant unmet need, D-PLEX100 has the potential to make a substantial market impact. We remain on track for an NDA submission in early 2026 and believe these robust data will serve as a strong catalyst for advancing our global partnership discussions. We are deeply grateful to the patients, principal investigators, and study teams who made this milestone possible."
Key findings from SHIELD II study include:
<ul>
<li>The primary efficacy endpoint of the study was successfully met, with a significantly lower proportion of primary endpoint events among patients who received D-PLEX100 plus SoC (n=405; 10.9%), compared to SoC alone (n=393; 18.1%), representing a 38% reduction (p&lt;0.005). The primary endpoint is the combination of deep and superficial SSIs, all-cause mortality and surgical reinterventions at the same incision of the original index surgery. &nbsp;</li>
<li>SHIELD II included three key secondary endpoints: 
<ul>
<li>The first key secondary endpoint was met, with a 58% reduction in deep and superficial SSI rates among patients who received D-PLEX100 plus SoC (3.8%) compared to those who received SoC alone (9.5%) (p&lt;0.005). &nbsp;</li>
<li>The second key secondary endpoint showed statistical significance in favor of D-PLEX100 plus SoC over SoC alone (p&lt;0.005). This efficacy endpoint combined SSI, mortality and reintervention as evaluated in the primary endpoint. This endpoint was assessed in the overall study population of 975 patients with an incision ≥7 cm, including laparoscopic surgery patients enrolled prior to the 2023 trial protocol change. &nbsp;</li>
<li>The third key secondary endpoint was met with a 62% reduction of patients with an ASEPSIS1&nbsp;score &gt;20 in D-PLEX100 plus SoC arm compared to SoC alone arm (p&lt;0.05). The ASEPSIS score is a clinical tool used to objectively assess surgical wound infections. &nbsp;</li>
</ul>
</li>
<li>There were no safety concerns raised by the independent Data Safety Monitoring Board in SHIELD II.</li>
</ul>

PYPD

PolyPid's Surgery Drug Cuts Infection Risk by 38% in Major Phase 3 Trial

Crypto markets opened the week on on Mondya morning, buoyed by <a href="https://www.benzinga.com/markets/ipos/25/06/45819104/cathie-wood-calls-circles-ipo-an-amazing-debut">Circle's IPO success</a>, which has rekindled optimism in the broader crypto sector. The move also sparks anticipation for more public listings from major crypto firms like Gemini, Kraken and Chainalysis.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$107,327.87</td>
<td>+1.7%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,532.52 </td>
<td>+1%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$155.28</td>
<td>+4.1%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.26</td>
<td>+1.9%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1853</td>
<td>+1.3%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001267</td>
<td>+1.4%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum large transaction volume decreased by 2.4% and 1% respectively. Daily active addresses are down by 5% and 1.7% each in a single day. BTC's exchange netflows are up by 179.3%.</li>
<li>Coinglass data shows 57,771 traders were liquidated in the past 24 hours for $133.66 million.</li>
<li>SoSoValue data shows net outflows of $47.8 million into spot Bitcoin ETFs. Spot Ethereum ETFs saw net inflows of $25.2 million.</li>
</ul>
Trader Notes: Crypto analyst Kevin <a href="https://x.com/Kev_Capital_TA/status/1931866716352770230">revealed</a> he's been on the sidelines after taking profits on altcoins last month, citing the past four weeks of "truly diabolical" and unprecedented volatility in the crypto market. He remains cautious, awaiting more stable setups.
Meanwhile, trader Jelle <a href="https://x.com/CryptoJelleNL/status/1931984820072018033">remains</a> bullish, noting that global money supply is expanding, which he believes will drag Bitcoin higher, targeting $140,000. Technical analyst Ali Martinez emphasized a critical level: Bitcoin needs a confirmed close above $106,900 to validate further upside. If rejected, BTC could fall back toward $105,000 or even $103,500.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Wait for a sustained close above $106,900 before you turn bullish on <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> because a rejection here could send it back to $105,000 or even $103,500. <a href="https://t.co/ojwWu7pKdG">pic.twitter.com/ojwWu7pKdG</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1932015913634533616?ref_src=twsrc%5Etfw">June 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to More Crypto Online, SOL <a href="https://x.com/Morecryptoonl/status/1932017332743725538">remains</a> bullish as long as the $143.95–$148.28 support zone holds. A rebound from this level could kick off the next leg higher.
Trader Wolf <a href="https://x.com/IamCryptoWolf/status/1932000494207062421">believes</a> ETH is in a healthy consolidation phase following May's strong rally. A final sweep of the lows could still occur before a move higher resumes.
Analyst Kamran Ashgar highlights an ascending broadening wedge pattern. If DOGE breaks out above $0.47, it could rally toward the $3.80 textbook target.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> maintains a strong structure within an Ascending Broadening Wedge &#x1f525; The target remains 3.8 as the pattern target.&#x1f680;<a href="https://twitter.com/search?q=%24Doge&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$Doge</a> <a href="https://t.co/cak0hcX1IJ">pic.twitter.com/cak0hcX1IJ</a>
&mdash; 
</blockquote></div></figure>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Start The Week Green Ahead Of US-China Trade Talks

Patent issuance expands United States patent coverage for AVERSA&#x2122; transdermal abuse deterrent technology
AVERSA&#x2122; transdermal abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
ORLANDO, Fla., June 09, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRBW#NASDAQ">NTRBW</a>), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that the United States Patent and Trademark Office (USPTO) issued patent number 12,318,492 on June 3, 2025, entitled "Abuse and Misuse Deterrent Transdermal Systems." The issuance of this patent further expands Nutriband's intellectual property protection in the United States for its portfolio of abuse deterrent transdermal products based on its proprietary Aversa&#x2122; abuse deterrent technology. This technology can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.
The AVERSA&#x2122; abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
Nutriband's lead product under development is Aversa&#x2122; Fentanyl, an abuse deterrent fentanyl transdermal system, with the potential to become the first abuse deterrent pain patch on the market with peak annual US sales estimated to be$80 million to $200 million.

NTRB

NTRBW

Nutriband Says Patent Issuance Expands US Patent Coverage For AVERSA Transdermal Abuse Deterrent Technology

HC Wainwright &amp; Co. analyst Joseph Pantginis assumes Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) with a Buy rating and announces Price Target of $4.

Initiation

MBRX

HC Wainwright & Co. Assumes Moleculin Biotech at Buy, Announces Price Target of $4

Results are from Acurx's ongoing scientific collaboration with Leiden University Medical Center (LUMC) partially under a grant from Health Holland to further study the mechanism of action of&nbsp;DNA pol IIIC inhibitors
LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues Novel chemotype specifically targeting gram-positive bacteria through an unexploited target Ibezapolstat ready to enter pivotal Phase 3 clinical trials for C. difficile Infection (CDI), with no cross resistance reported to date
Ibezapolstat has previously been granted FDA QIDP and Fast-Track Designations and has received SME (Small and Medium-sized Enterprise) designation by the EMA
STATEN ISLAND,&nbsp;N.Y., June 9, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. Its&nbsp;lead&nbsp;antibiotic&nbsp;candidate,&nbsp;ibezapolstat (IBZ), is&nbsp;ready&nbsp;to&nbsp;advance to&nbsp;international&nbsp;pivotal Phase&nbsp;3 clinical&nbsp;trials&nbsp;for treatment of&nbsp;patients&nbsp;with&nbsp;C.&nbsp;difficile&nbsp;infection&nbsp;(CDI).
The&nbsp;Company today&nbsp;announced that a presentation of a poster and an oral presentation regarding Acurx's overall DNA pol IIIC inhibitor platform was presented at a scientific conference on May 21 by Mia Urem, PhD, from Leiden University Medical Center in the Netherlands entitled: "A Unique Inhibitor Conformation Selectively Targets the DNA Polymerase PolC of Gram-Positive Priority Pathogens".&nbsp; This scientific conference is sponsored by the Federation of American Societies for Experimental Biology and is the premier venue for the newest research and technological trends in molecular "machines" inside the human body that ensure DNA replication and expression of genes to create proteins that make up a cell. The distinctive non-planar conformation of ACX-801 and IBZ, together with high conservation of the induced binding pocket in PolC, suggests that this is a general mechanism for this class of inhibitor and is conserved in Gram-positive bacteria.

ACXP

Acurx Pharma Says Lead Antibiotic Candidate, Ibezapolstat, Is Ready To Advance To International Pivotal Phase 3 Clinical Trials For Treatment Of Patients With C. Difficile Infection

HC Wainwright &amp; Co. analyst Brandon Folkes initiates coverage on Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) with a Buy rating and announces Price Target of $6.

HRTX

HC Wainwright & Co. Initiates Coverage On Heron Therapeutics with Buy Rating, Announces Price Target of $6

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) with a Buy and maintains $20 price target.

Reiteration

PHAT

HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $20 Price Target

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Outbrain Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>), which is operating under the new Teads brand following Outbrain's acquisition of Teads in February 2025, announced today that the combined company has completed its corporate renaming from "Outbrain Inc." to "Teads Holding Co." The combined company will begin trading under the new ticker symbol "TEAD" on the Nasdaq effective June 10, 2025.
The change will not impact current stockholders, contracts, or operations. No action is required by shareholders in connection with the name change.

Outbrain Completes Name Change to Teads Holding Co., To Begin Trading Under New Nasdaq Symbol 'TEAD' Effective June 10

ONDS

Ondas Lands $14.3M Optimus System Order From Major Defense Customer, Largest To Date

Oddity Finance Announces $350M Offering Of 0% Exchangeable Senior Notes Due 2030

Press Releases

Gambling.com Group Reports Third Quarter 2024 Results and Raises 2024 Guidance

Gambling.com Group Enters into Definitive Agreement to Acquire Odds Holdings, Parent Company of OddsJam, a Fast-Growing Technology Platform for Real-time Odds Data, in Accretive Transaction

Gambling.com Group Completes Acquisition of Odds Holdings, Inc., Parent Company of OddsJam

Gambling.com Group Announces Preliminary Record 2024 Fourth Quarter Revenue of Approximately $35.2 Million, Net Income of Approximately $7.8 Million and Adjusted EBITDA of Approximately $14.7 Million

Comments

Gambling.com Gr

Interés en corto

Gambling.com Gr (NASDAQ:GAMB) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL